Paul C. Grint, M.D.
Dr. Grint joined Regulus in June 2014 as Chief Medical Officer and was appointed President and Chief Executive Officer in June 2015. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of numerous products in oncology, anti-infectives and immunology in both domestic and international markets. Prior to joining Regulus, Dr. Grint was President of Cerexa, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc., where he was responsible for the oversight of anti-infective product development. Prior to that, Dr. Grint served as Senior Vice President of Research at Forest Research Institute, Inc., Chief Medical Officer at Kalypsys, Inc. and he also served in similar executive level positions at Pfizer Inc., IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation. Dr. Grint received his bachelor’s degree from St. Mary’s Hospital in London and his medical degree from St. Bartholomew’s Hospital Medical College at the University of London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or co-author of over fifty scientific publications.